Submission Checklist

Final Verification Before Manuscript Submission

Authors should verify every applicable item before submitting a manuscript to the Journal of Public Health and Pharmacy. Manuscripts that do not meet the journal's scope, technical, scientific, ethical, reporting, formatting, or administrative requirements may be returned for correction or declined during editorial screening.

A. Scope, Relevance, Originality, and Author Approval

☐ The manuscript is consistent with the official JPHP Focus and Scope.

☐ The manuscript has a clear and substantial relationship with at least one JPHP scope area.

☐ The manuscript addresses epidemiology, including disease distribution, patterns, determinants, risk factors, prevention, or population disease burden; or this item is not applicable.

☐ The manuscript addresses health education and behavioral science, including health literacy, health behavior, psychosocial determinants, community participation, or behavior-change interventions; or this item is not applicable.

☐ The manuscript addresses environmental health or occupational safety, including environmental exposure, sanitation, pollution, workplace hazards, worker health, risk assessment, or preventive intervention; or this item is not applicable.

☐ The manuscript addresses health administration or policy, including governance, healthcare administration, service delivery, access, quality, financing, workforce management, program implementation, or policy evaluation; or this item is not applicable.

☐ The manuscript addresses reproductive health, including maternal health, sexual and reproductive health, family planning, adolescent reproductive health, reproductive services, rights, interventions, or policy; or this item is not applicable.

☐ The manuscript addresses health economics or economic evaluation, including cost-effectiveness, cost-utility, cost-benefit, budget impact, affordability, resource allocation, or economic efficiency; or this item is not applicable.

☐ The manuscript addresses the role of pharmacy in public health, including access to essential medicines, rational medicine use, medication adherence, medication safety, community pharmacy services, pharmaceutical policy, or pharmacist-led public-health interventions; or this item is not applicable.

☐ The public-health relevance, population-level contribution, policy implication, or practical value is stated explicitly.

☐ The public-health or population-health contribution is reflected consistently in the objectives, methods, results, discussion, and conclusion.

☐ The manuscript is not limited exclusively to basic pharmaceutical chemistry, drug formulation, laboratory product development, isolated clinical diagnosis, individual clinical treatment, or pharmaceutical efficacy without an explicitly evaluated public-health contribution.

☐ The manuscript is not a community-service report without a research design.

☐ The manuscript is not an opinion article without analytical evidence.

☐ A review manuscript uses transparent and reproducible methods.

☐ The correct article type has been selected: Original Research Article, Review Article, or Brief Report.

☐ A Brief Report, when submitted, presents concise but scientifically valid findings with clear relevance to the JPHP scope.

☐ The manuscript has not been published previously in substantially the same form.

☐ The manuscript is not under consideration by another journal.

☐ The manuscript is original and does not contain plagiarism, inappropriate text recycling, fabrication, falsification, or image manipulation.

☐ The manuscript does not represent fragmented or redundant publication without adequate scientific justification.

☐ All authors have reviewed and approved the final manuscript.

☐ All authors have approved the authorship order and submission to JPHP.

☐ Every listed author meets accepted authorship criteria.

☐ No eligible contributor has been omitted from the author list.

☐ Individuals who do not meet authorship criteria are acknowledged appropriately and with permission.

B. Required Submission Files

☐ The official JPHP Title Page Template has been used.

☐ The official JPHP Anonymized Main Document Template has been used.

☐ The Title Page and Anonymized Main Document are uploaded as separate files.

☐ A complete similarity report has been prepared.

☐ The similarity report corresponds to the final submitted manuscript.

☐ The overall similarity index does not exceed 20%.

☐ Sources of text overlap have been reviewed and corrected where necessary.

☐ All bracketed placeholders have been replaced with manuscript-specific information.

☐ All instructional text, sample content, highlights, comments, and guidance notes have been deleted.

☐ All tracked changes have been accepted or rejected.

☐ Supplementary files have been uploaded where applicable.

☐ All uploaded files open correctly and contain the intended final version.

☐ File names are clear, professional, and consistent with their contents.

C. Double-Blind Peer Review

☐ The Anonymized Main Document does not contain author names.

☐ The Anonymized Main Document does not contain author affiliations.

☐ The Anonymized Main Document does not contain author email addresses, telephone numbers, or ORCID iDs.

☐ Acknowledgments appear only in the Title Page.

☐ Author-contribution statements appear only in the Title Page.

☐ Identifying funding and conflict-of-interest information appears only in the Title Page.

☐ Self-citations are written neutrally and do not reveal authorship unnecessarily.

☐ Institutional information has been anonymized only where necessary to protect peer-review integrity.

☐ Essential ethics approval and registration information remains available for editorial assessment.

☐ Author-identifying information has been removed from document properties and file metadata.

☐ Tracked changes, comments, revision history, hidden text, and annotations have been removed.

☐ The Anonymized Main Document file name does not reveal author or institutional identity.

D. Title Page Information

☐ The article type is stated clearly.

☐ The full article title is complete, accurate, concise, and informative.

☐ The title reflects the study design, population, intervention, exposure, or principal topic where appropriate.

☐ A short title of no more than 50 characters, including spaces, is provided.

☐ All author names are written correctly and in the agreed order.

☐ Author names are written consistently with institutional records and previous publications.

☐ Author affiliations include department or unit, faculty or institution, city, and country.

☐ The corresponding author is identified clearly.

☐ The corresponding-author postal address and email address are complete and current.

☐ Every supplied ORCID iD belongs to the correct author.

☐ ORCID iDs are written using the complete https://orcid.org/ URL.

☐ Manuscript word count is provided.

☐ Reference, table, figure, and supplementary-file counts are provided.

☐ All required publication declarations are included.

E. Manuscript Structure, Public-Health Relevance, and Academic Content

☐ The manuscript follows the structure required for the selected article type.

☐ The abstract accurately summarizes the objective, methods, principal results, and conclusion.

☐ The abstract identifies the population-health, public-health, policy, or pharmacy-related relevance of the study where appropriate.

☐ The abstract is consistent with the data reported in the main text.

☐ The abstract contains no citations.

☐ The abstract contains no undefined abbreviations, tables, figures, or identifying details.

☐ Three to six relevant and standardized keywords are provided.

☐ Keywords are separated by semicolons.

☐ The Introduction explains the public-health or population-health problem, relevant evidence, unresolved gap, rationale, and objective or hypothesis.

☐ The Introduction explains how the study relates to at least one official JPHP scope area.

☐ The Methods provide sufficient information for scientific evaluation and replication.

☐ The Methods are capable of evaluating the claimed public-health, population-health, policy, economic, behavioral, environmental, occupational, reproductive-health, or pharmacy-related contribution.

☐ The Results follow the order of the objectives, outcomes, or analytical plan.

☐ The Results report findings relevant to the claimed JPHP scope area.

☐ The Results distinguish primary findings from secondary or exploratory analyses.

☐ The Discussion interprets rather than merely repeats the findings.

☐ The Discussion compares the findings with relevant previous evidence.

☐ The Discussion addresses plausible mechanisms, strengths, limitations, bias, and implications.

☐ The Discussion explains the implications for public-health research, policy, administration, prevention, health education, healthcare delivery, or pharmacy-related public-health practice.

☐ The Conclusion directly addresses the study objective.

☐ The Conclusion states the public-health, population-health, policy, or practical significance without overstating the evidence.

☐ The Conclusion does not introduce new data.

☐ The Conclusion does not overstate causality, effectiveness, novelty, or generalizability.

☐ The manuscript is written in clear, concise, grammatically correct, and academically appropriate English.

☐ Abbreviations are defined at first use and applied consistently.

☐ Generic medicine names are used unless a trade name is scientifically necessary.

☐ International System of Units is used where applicable.

F. Methods, Measurement, and Analysis

☐ The study design is identified accurately.

☐ The analytical or conceptual framework is stated where relevant.

☐ The setting, geographic scope, institutional context, and study period are reported.

☐ The population, community, healthcare system, service, workforce, policy environment, or public-health setting is described clearly.

☐ Eligibility and exclusion criteria are reported.

☐ Sampling and recruitment procedures are explained.

☐ Sample-size calculation, statistical power, or another sample-size justification is provided.

☐ Variables, outcomes, exposures, interventions, covariates, confounders, and operational definitions are described.

☐ Population-level, service-level, policy-level, behavioral, environmental, occupational, reproductive-health, economic, or medicine-related outcomes are defined where applicable.

☐ Measurement instruments and data sources are identified.

☐ Validity, reliability, calibration, or measurement-quality information is provided where applicable.

☐ Data-collection procedures are described transparently.

☐ Data-management and quality-control procedures are reported.

☐ Statistical, qualitative, economic, policy, implementation, or mixed-methods analyses are appropriate to the research question and data.

☐ Analytical procedures are described with sufficient detail for evaluation and replication.

☐ Software names, versions, packages, or major analytical tools are reported.

☐ Effect measures and confidence intervals are reported where appropriate.

☐ Exact p-values are reported where appropriate.

☐ Statistical significance is distinguished from public-health, policy, economic, behavioral, environmental, occupational, reproductive-health, or pharmaceutical significance.

☐ Missing-data procedures are explained.

☐ Participant exclusions, outliers, and protocol deviations are reported.

☐ Model assumptions, diagnostics, validation, adjustment variables, and sensitivity analyses are reported where relevant.

☐ Prespecified analyses are distinguished from exploratory or post hoc analyses.

☐ Causal language is consistent with the study design.

G. Reporting Guidelines

☐ The reporting guideline appropriate to the study design has been identified.

☐ The manuscript complies with the applicable reporting guideline.

☐ The latest applicable version or extension of the guideline has been used.

☐ More than one guideline has been applied when required by the study design.

☐ The completed reporting checklist is ready for upload when requested.

☐ Page or section references in the checklist correspond to the final manuscript.

☐ Items marked not applicable genuinely do not apply and are explained where necessary.

☐ Randomized trials include the applicable CONSORT flow diagram.

☐ Systematic or scoping reviews include a study-selection flow diagram.

☐ Intervention studies provide sufficient detail for replication.

☐ Review protocols and registrations are reported where available.

H. Ethics, Registration, and Research Integrity

☐ The name of the ethics committee or institutional review board is provided where required.

☐ The ethics approval number and approval date are reported where applicable.

☐ Any ethics exemption or waiver is explained and documented.

☐ Informed-consent procedures are stated.

☐ Consent for publication has been obtained where an individual may be identified.

☐ Participant confidentiality and data protection have been addressed.

☐ Clinical-trial registration details are provided where applicable.

☐ Protocol registration details are provided where applicable.

☐ The registration was completed at the appropriate stage of the study.

☐ The reported study is consistent with the approved protocol or registration.

☐ Deviations from the protocol are disclosed and explained.

☐ No data, image, result, participant record, or research document has been fabricated, falsified, or manipulated.

☐ Any correction, retraction, or expression of concern relevant to cited work has been considered.

I. Authorship, Funding, Conflicts of Interest, and Transparency

☐ Author contributions are described using appropriate CRediT roles.

☐ The contribution statement accurately reflects each author's work.

☐ Funding sources and grant numbers are stated.

☐ The role of the funder in study design, data collection, analysis, interpretation, writing, and publication decisions is disclosed.

☐ Financial conflicts of interest are disclosed.

☐ Nonfinancial conflicts of interest are disclosed.

☐ A data-availability statement is included.

☐ Conditions for accessing restricted data are explained.

☐ Availability of protocols, instruments, materials, code, or supplementary data is stated where relevant.

☐ Generative artificial intelligence or AI-assisted technology use is declared when applicable.

☐ The AI declaration identifies the tool and purpose of use where required.

☐ No AI tool is listed as an author.

☐ Authors accept responsibility for the accuracy and integrity of AI-assisted content.

☐ Individuals named in the acknowledgments have agreed to be identified.

☐ Professional writing, translation, statistical, or technical assistance is acknowledged where appropriate.

J. Pharmacy in Public Health

☐ The pharmacy-related study demonstrates a clear connection to population health or public-health practice.

☐ The study addresses access to essential medicines, rational medicine use, medication adherence, medication safety, community pharmacy services, pharmaceutical policy, or pharmacist-led public-health intervention; or clearly explains another relevant public-health contribution.

☐ The population, community, healthcare-service, policy, access, safety, adherence, or medicine-use outcome is defined clearly.

☐ The pharmacy-practice or pharmaceutical-policy setting is described.

☐ Generic medicine names are used consistently.

☐ Dosage forms, strengths, routes, frequencies, and treatment durations are reported when relevant to the public-health question.

☐ Medicine-access, adherence, prescribing, dispensing, utilization, or medication-safety definitions are stated clearly.

☐ Drug-utilization denominators, observation periods, and population bases are reported.

☐ Adverse-event definitions, classifications, and causality-assessment methods are reported where applicable.

☐ Pharmacist-led interventions describe providers, setting, target population, intervention components, duration, and outcomes.

☐ Pharmaceutical-policy studies identify the policy context, implementation environment, affected population, and relevant outcomes.

☐ Clinical or pharmaceutical findings are interpreted in terms of population health, medication safety, access, service delivery, policy, prevention, or public-health practice.

☐ A laboratory, formulation, product-development, clinical-treatment, or pharmaceutical-efficacy study includes an explicitly evaluated and substantial public-health contribution.

☐ The manuscript does not rely solely on laboratory, chemical, formulation, or individual clinical outcomes to claim relevance to JPHP.

☐ Public-health or population-health relevance is discussed in addition to statistical or pharmaceutical significance.

K. References

☐ Citations are numbered in order of first appearance.

☐ References follow Vancouver style consistently.

☐ Every in-text citation appears in the reference list.

☐ Every listed reference is cited in the manuscript.

☐ Author names, article titles, journal titles, years, volumes, issues, and page numbers have been verified.

☐ DOI information is included in a complete and resolvable format where available.

☐ Stable URLs are included only where appropriate.

☐ References are relevant, traceable, authoritative, and sufficiently current.

☐ Primary sources are cited where appropriate.

☐ References support the manuscript's claimed relationship with the relevant JPHP scope area.

☐ References have not been added solely to influence citation metrics.

☐ Retracted articles are not cited as valid evidence.

☐ Any citation of a retracted article is clearly identified and scientifically justified.

☐ No fabricated or unverifiable reference is included.

L. Tables, Figures, and Supplementary Materials

☐ Tables and figures are numbered in order of first citation.

☐ Every table and figure is cited in the manuscript text.

☐ Table titles are clear and self-explanatory.

☐ Figure legends are complete and understandable without excessive reference to the main text.

☐ Abbreviations and statistical annotations are defined in table notes and figure legends.

☐ Units, denominators, sample sizes, and measures of variability are reported.

☐ Population, service, policy, intervention, environmental, occupational, reproductive-health, economic, or medicine-use denominators are clear where applicable.

☐ Data are not duplicated unnecessarily across the text, tables, and figures.

☐ Figures are legible and of publication quality.

☐ Images have not been altered in a misleading manner.

☐ Image adjustments, if any, have been applied consistently and do not obscure or misrepresent data.

☐ Sources are acknowledged for reproduced or adapted materials.

☐ Written permission has been obtained for copyrighted material where required.

☐ Supplementary files are cited and labeled consistently.

☐ Supplementary files do not contain unnecessary author-identifying information.

M. OJS Metadata and Final Confirmation

☐ The title entered in OJS matches the final manuscript title exactly.

☐ The abstract entered in OJS matches the final submitted abstract.

☐ The keywords entered in OJS match the final manuscript keywords.

☐ The selected OJS section or article type is correct.

☐ The OJS metadata accurately reflects the manuscript's JPHP scope area.

☐ All authors have been entered into OJS in the correct order.

☐ Author names in OJS match the Title Page.

☐ Author affiliations, countries, and email addresses are accurate.

☐ The corresponding author is identified correctly in OJS.

☐ ORCID iDs entered in OJS are accurate.

☐ Funding and supporting-agency metadata are complete where applicable.

☐ All required files have been uploaded.

☐ Every file has been assigned the correct submission component or label.

☐ Manuscript files, supplementary files, and OJS metadata are mutually consistent.

☐ The corresponding author is authorized to communicate with the journal on behalf of all authors.

☐ All authors accept accountability for the accuracy and integrity of the submission.

☐ All authors understand that submission does not guarantee external peer review or acceptance.